ArticleAnnals of translational medicine2021

Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion.

Yingying Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.